4//SEC Filing
DiBiase Mary 4
Accession 0001628280-24-040128
CIK 0001501697other
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 4:01 PM ET
Size
5.5 KB
Accession
0001628280-24-040128
Insider Transaction Report
Form 4
DiBiase Mary
Chief Operating Officer
Transactions
- Sale
Common Stock
2024-09-09$0.66/sh−2,642$1,738→ 289,110 total
Footnotes (2)
- [F1]Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.6548 to $0.6646, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001880179
Filing Metadata
- Form type
- 4
- Filed
- Sep 10, 8:00 PM ET
- Accepted
- Sep 11, 4:01 PM ET
- Size
- 5.5 KB